



17010172

*Centras*



**Nasdaq**

Stock Market


*1-37998*

**William Slattery, CFA**  
Vice President  
Listing Qualifications

Electronic Mail Only

January 26, 2017

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549



Dear Mr. Thomas:

This is to certify that on January 25, 2016 The Nasdaq Stock Market (the "Exchange") received from Jounce Therapeutics, Inc. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Common Stock, par value \$0.001 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

*William Slattery*

*CA*